Neurol. praxi. 2009;10(6):384-389

Treating Alzheimer’s disease and related neurodegenerative dementias

doc.MUDr.Roman Jirák, CSc.
Psychiatrická klinika 1. LF UK Praha

Dementias of neurodegenerative origin represents big therapeutical problem for its frequency (Alzheimer´s disease is most common

dementia), health and social unadvisability (diseases devastating the quality of life and in most cases with letal end), for its financial

expensiveness and for its difficult currability. In most cases of these diseases is not known its ethiology and pathogenesis completely

at present time, and thus our contemporary treatment results from the affection of known pathogenetic mechanisms. Therapy of neurodegenerative

dementias includes pharmacotherapy of cognitive functions, pharmacotherapy of non-cognitive functions, therapy

of intercurrent static disorders, psychotherapy (first of all reeducation), sociotherapy and cooperation with caregivers – closest family

members. In the article there are discussed basic possibilities of above mentioned therapeutic approaches.

Keywords: Alzheimer´s disease, dementia, pharmacotherapy, Lewy body disease, neurodegeneration, reeducation

Published: January 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jirák R. Treating Alzheimer’s disease and related neurodegenerative dementias. Neurol. praxi. 2009;10(6):384-389.
Download citation

References

  1. Aisen PS. Tarenflurbil: a shot on goal. Lancet Neurology, 2008; 7(6): 468-469. Go to original source... Go to PubMed...
  2. Black SE, Doody R, Li H, McRae T, Jambor KM, Xu Z, Sun Z, Perdomo CA, Richardson C. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology 2007; 69(5): 459-468. Go to original source... Go to PubMed...
  3. Brodaty H, Green Al, Koschera A. Meta-Analysis of Psychosocial Interventions for Caregivers of People with Dementia, Journ of Amer Geriatr Society 51, 1-8, 2003. Go to original source... Go to PubMed...
  4. Caltagirone C, Bianchetti A, Di Luca M, Mecocci P, Padovani A, Pirfo E, Scapichcio P, Semin U, Trabuchci M, Musicco M, Italian Association of Psychogeriatrics. Guidelines for the treatment of Alzheimer´s disease from the Italian Association of Psychogeriatrics. Drugs & Aging 2005; 22 Suppl. 1: 1-26. Go to original source... Go to PubMed...
  5. Czirr E, Leuchtenberger S, Dorner-Ciossek C, Schneider A, Jucker M, Koo EH. Intensivity to AB42-lowering Nonsteroidal antiinflammatory drugs and gamma-secretase inhibitors is common among aggressive presenilin-1 mutations. J Biol Biochem 2007; 282(34): 24504-24513. Go to original source...
  6. De Vugt ME, Stevens F, Aalten P, Lousberg R, Jaspers N, Winkens I, Jolles J, Verhey FR. Do caregiver management strategies influence patient behaviour in dementia?, Internat Journ of Geriatr Psychiatry 2004; 19: 85-92. Go to original source... Go to PubMed...
  7. Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurim SO, Seely L, Hung D, dimebon investigators. Effect of dimebon on cognition, activities of daily living, behaviour, and global fiction in patiens with mild-to-moderate Alzheimer´s disease: a randomised, double-blind, placebo-controlled study. The Lancet, 2008; 372: 207-215. Go to original source... Go to PubMed...
  8. Famer D, Meaney S, Mousavi M, Nordberg A, Björkhem I, Crisby M. Regulation of alfa- and beta-secretase aktivity by oxysterols: cerebrosterol stimulans processing of APP via the alfa-secretase pathway. Biochem Biophys Res Commun., 2007; 359: 46-50. Go to original source... Go to PubMed...
  9. Holmes C, Boche D, Wilkonson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, Zotova E, Nicoll JAR. Long-term effects of AB42 immunisation in Alzheimer´s disease: follow-up of a randomised, placebo-controlled phase I trial. The Lancet, 2008; 372: 216-223. Go to original source... Go to PubMed...
  10. Hooper C, Killick R, Lovestone S. The GSK3 hypothesis of Alzheimer´s disease. J Neurochem. 2007 Dec 18 [Epub ahead of print]. Go to original source... Go to PubMed...
  11. Christensen DD. Changing the course of Alzheimer´s disease: Anti-amyloid disease-modifying treatments on the horizon. Prim Care Companion J Clin Psychiatry 2007; 9(1): 32-41. Go to original source... Go to PubMed...
  12. Jirák R, Koukolík F. Demence. Neurobiologie, klinický obraz, terapie. Galén, 2004, vydání 1.
  13. Jirák R, Borzová C, Konrád J, Franková V, Spousta S. Demence. In: Psychiatrie. Doporučené postupy psychiatrické péče II, ed. Raboch J, Anders M, Praško J, Hellerová P. Infopharm, Praha, 2006: 22-37.
  14. Kim J, Onstead L, Randle S, Price R, Smithson L, Zwisinski C, Dickson DV, Golde T, McGowan E. AB inhibits amyloid deposition in vivo. The Journal of Neuroscience, 2007; 27(3): 627-633. Go to original source... Go to PubMed...
  15. McConlogue L, Buttini M, Anderson JP, Johnson-Wood R, Lee M, Zeller M, Liu W, Motter R, Sinha S. Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP transgenic mice. J Biol Chem 2007; 282(36): 26326-26334. Go to original source... Go to PubMed...
  16. NICE guideline: CG42 Dementia; http://guidance.nice.org.uk/cg42/niceguidance/pdf/English (22. 4. 2009).
  17. Peskind ER, Potkin SG, Pomara, OH BR, Graham SN, Olin JT, McDonald S, for the Memantine MEM-MD-10 Study Group. Memantine treatment in mild to moderate Alzheimer disease: a 24 week randomized controlled trial. Am J Geriatr Psychiatry 2006; 14(8): 704-715. Go to original source... Go to PubMed...
  18. Ringman JM, Frautschy SA, Cole GM, Masterman DL, Cummings J. A potential role of the curry spice curcumin in Alzheimer´sdisease. Current Alzheimer Reswearch, 2005; 2(2): 1-6. Go to original source... Go to PubMed...
  19. Santa-Maria I, Hernandez F, Del Rio J, Morens FJ, Avila J. Tramiprosate, a drug of potential interest for the treatment of Alzheimer´s disease, promotes an abnormal aggregation of tau. Mol Neurodegener, 2007; 2(1): 17. Go to original source... Go to PubMed...
  20. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil. A randomized, controlled trial. JAMA, Jan. 21, 2004; 291(3): 317-324. Go to original source... Go to PubMed...
  21. Townsend K, Pratico D. Novel therapeutic opportunities for Alzheimer´s disease: focus on nonsteroidal anti-inflammatory drugs. The FASEB Journal, 2005; 19: 1592-1601. Go to original source... Go to PubMed...
  22. Vasilevko V, Xu F, Previti ML, Van Nostrand WE, Cribbs DH. Experimental investigation of antibody-mediated clearance mechanisms of amyloid in CNS of Tg-SwDI transgenic mice. J Neurosci 2007; 27(49): 13376-13383. Go to original source... Go to PubMed...
  23. Walker LC, Rosen RF. Alzheimer therapeutics - what after the cholinesterase inhibitors? Age and Ageing 2006; 35(4): 332-335. Go to original source... Go to PubMed...
  24. Wang JZm, Grundke-Iqbal I, Iqbal K. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur J Neurosci, 2007; 25(1): 59-68. Go to original source... Go to PubMed...




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.